Member Info for closettrader

....and the now invalid results of the Phase III trial in March 2019 caused a 40% drop in the share price at the time.....

Birch trees have a main pollen season during April and May. Approximately 25% of hayfever sufferers are allergic to birch. The results in March 2019 of a phase III trial conducted in Germany for AGY, which apparently gave a statistically insignificant difference between placebo andactive arms of the study, has now been proved to be invalid and will be retrialled. As the CEO said in today's RNS, 'We remain committed to Birch MATA MPL, especially considering the results of the independent secondary endpoint data and the supportive safety profile observed in the B301 study and two successful phase II trials showing significant primary efficacy results.' ....and the MM's marked this down 25% on opening despite this being positve news for AGY.......shocking!!

Proactive@proactive_UK20h
$TILS Tiziana Life Sciences diagnostics spinout could be worth significantly more than Tiziana itself, says Wall Street analyst http://tinyurl.com/ybdfhnd4 via
@proactive_UK@tizianals #TILS
Apologies if posted already

Where's the Chilean Metals money coming from? The latest financial statement (to Dec 2018) shows cash of $30000CAN. The Chilean Metals share price has also collapsed - in 1996 it was $180 CAN....now its $0.1CAN........

Depends on the upfront fee (plus the 2nd payment) paid to HAYD from IRPC - from RNS of June 29:
'The sustainable process sees Haydale functionalise IRPC's acetylene black product to create the organic RFID ink. The success of this collaboration is expected to pave the way to numerous opportunities in printed electronic applications and be more environmentally friendly than existing inks. The RFID printer market is expected to be a significant market with the global market expected to reach approximately USD 4.82 billion by the end of 2023.

Under the Agreement IRPC will pay an upfront fee to Haydale following signing of contract, with a second payment following submission of the final report.'

With the 2 lots of recent significant news this share is looking very good.....love the shape of the weeks chart

It was in the previous RNS regarding the phase ll collaboration between IRPC and HAYD

'2020 performance to exceed market expectations' - as stated in RNS of June 24, ' are expected to deliver a net profit for the year significantly above market expectations.

The Board looks forward to providing a further update to shareholders for the year to 30 June 2020 in the week commencing 13 July 2020.'

.........so that's in about 10 trading days time. Should be interesting.........

Commercialising their graphene inks in a huge market with the help of a billion pound Thai company....and this share used to be over £2.......

or maybe HAYD.........

I'm very happy that our small £7m mcap company is being paid upfront fees by an over £1bn mcap Thai petrochemicals company to collaborate on a market that is anticipated to be worth almost $5bn by 2023.....as the IRPC VP said, ' working closely with Haydale will enable us to capture great opportunity in IoT megatrend."....and as RH69 has said this share was over £2.00 only 4 years ago........

Well they certainly deliver profit...........

How many therapeutics are being tested in relation to Covid-19? I have done a fair amount of research on this disease and it seems that regarding consistently positive potential then its Remdesivir.....and us! With Sir Patrick Vallance saying twice in the Covid-19 update yesterday that therapeutics are the way forward, and that a vaccine will take quite a while, plus all the evidence that interferon is actively being tested and used, then I think this share will start to move up towards the end of the month in expectation of good results from Covid-19 hospital trials....and then there are the COPD results of course......

With thanks to PaulFG below:

One of the stand out quality metrics for Allergy Therapeutics is that it passes 6 of the 9 financial tests in the Piotroski F-Score. The F-Score is a world-class accounting-based checklist for finding stocks with an improving financial health trend. A good F-Score suggests that the company has strong signs of quality.
Fair price
While quality is important, no-one wants to overpay for a stock, so an appealing valuation is vital too. With a weaker economy, earnings forecasts are unclear right across the market. But there are some valuation measures that can help, and one of them is the Earnings Yield.
Earnings Yield compares a company's profit with its market valuation (worked out by dividing its operating profit by its enterprise value). It gives you a total value of the stock (including its cash and debt), which makes it easier to compare different stocks. As a percentage, the higher the Earnings Yield, the better value the share.
A rule of thumb for a reasonable Earnings Yield might be 5%, and the Earnings Yield for Allergy Therapeutics is currently 21.3%.

In summary, good quality and relatively cheap valuations are pointers to those stocks that are some of the most appealing to contrarian value investors. It's among these shares that genuine mis-pricing can be found. Once the market recognises that these quality firms are on sale, those prices often rebound.

Has this Company been totally overlooked by the market? Results to Dec 2019 give strong cash position of £40m and trading update RNS today states: 'Reported revenues for the year ended 30 June 2020 are expected to be at least 4% ahead of last year in constant currency terms. A programme of operating cost efficiencies, together with the timing of the planned research and development expenditure over the 3 years to June 2022, are expected to deliver a net profit for the year significantly above market expectations.

The Board looks forward to providing a further update to shareholders for the year to 30 June 2020 in the week commencing 13 July 2020.'

Could be a decent climb up to mid July in expectation of a further positive update.......

Just posted this on the MWG board as well:
Interesting piece in Saturday's Times (apologies if already posted) which could expand on MWG's work in Italy:
Sewage Study finds virus was in Italy last year. Coronavirus was in Italy in mid-December....a study of sewage water has found. Samples taken in Turin and Milan on Dec 18 contained traces of the virus.......'After the outbreak we were testing sewage for the virus and realised we could check back in time by analysing old frozen samples we held on to'.....Sufferers are thought to shed the virus in their faces from the moment they are infected, days before they show symptoms,meaning sewage testing could spot outbreaks up to two weeks before doctors.....'we are now planning continual sewage testing in Italian tourist towns on the Adriatic coast from July 1 ahead of national testing in the autumn to catch a possible second wave.....'

Interesting piece in Saturday's Times (apologies if already posted) which could expand on MWG's work in Italy:
Sewage Study finds virus was in Italy last year. Coronavirus was in Italy in mid-December....a study of sewage water has found. Samples taken in Turin and Milan on Dec 18 contained traces of the virus.......'After the outbreak we were testing sewage for the virus and realised we could check back in time by analysing old frozen samples we held on to'.....Sufferers are thought to shed the virus in their faces from the moment they are infected, days before they show symptoms,meaning sewage testing could spot outbreaks up to two weeks before doctors.....'we are now planning continual sewage testing in Italian tourist towns on the Adriatic coast from July 1 ahead of national testing in the autumn to catch a possible second wave.....'

Have been unable to buy anything over £500 worth all morning......

Interview this morning with Matt Han**** on BBC Breakfast where he emphasised that Dexamethasone was just for treating patients that had been admitted to hospital and confirming (as Sir Patrick Vallance did last night on CV update) that he was hopeful of other treatments in the pipeline that would help patients from having to go into hospital....and he looked extremely relaxed. So what other treatments are there out there that could reduce the possibility of patients having to go into hospital?.....well I can think of one......

On CV update tonight, Sir Patrick talking about Dexamethasone: 'This is the start of something important.......this is the start of other drugs that might be added on top of it to make an even bigger effect in due course we hope.'
Personally I don't think there'll be any drop in SNG share price tomorrow.......